← Back to home

PATIENTS MUST HAVE HISTOLOGICALLY OR CYTOLOGICALLY CONFIRMED LOCALLY ADVANCED OR METASTATIC NSCLC

Clinical trials for PATIENTS MUST HAVE HISTOLOGICALLY OR CYTOLOGICALLY CONFIRMED LOCALLY ADVANCED OR METASTATIC NSCLC explained in plain language.

Never miss a new study

Get alerted when new PATIENTS MUST HAVE HISTOLOGICALLY OR CYTOLOGICALLY CONFIRMED LOCALLY ADVANCED OR METASTATIC NSCLC trials appear

Sign up with your email to follow new studies for PATIENTS MUST HAVE HISTOLOGICALLY OR CYTOLOGICALLY CONFIRMED LOCALLY ADVANCED OR METASTATIC NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Single-Drug immunotherapy shows promise for advanced lung cancer

Disease control Recruiting now

This study looks at how well the immunotherapy drug ivonescimab works when used alone as the first treatment for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive) and no targetable gene mutations. About 265 participants will receive ivone…

Matched conditions: PATIENTS MUST HAVE HISTOLOGICALLY OR CYTOLOGICALLY CONFIRMED LOCALLY ADVANCED OR METASTATIC NSCLC

Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control

Last updated Jul 12, 2026 00:00 UTC

PATIENTS MUST HAVE HISTOLOGICALLY OR CYTOLOGICALLY CONFIRMED LOCALLY ADVANCED OR METASTATIC NSCLC

Get alerted when new PATIENTS MUST HAVE HISTOLOGICALLY OR CYTOLOGICALLY CONFIRMED LOCALLY ADVANCED OR METASTATIC NSCLC trials appear

Single-Drug immunotherapy shows promise for advanced lung cancer